Please ensure Javascript is enabled for purposes of website accessibility

3 Top Robinhood Stocks to Buy in August Instead of Dogecoin

By Alex Carchidi – Aug 1, 2021 at 6:28AM

Key Points

  • Dogecoin isn't a stable or safe investment, so it doesn't take much to make a stock a better bet.
  • Large pharmaceutical companies are among the safer choices in the market.
  • What biotechs lack in safety, they make up for with the potential for large and potentially rapid growth.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They might not hit the moon, but there's a much smaller chance they'll bite the dust.

If you've gotten burned by the latest Dogecoin (DOGE 5.34%) crash, you're not alone. The cryptocurrency started as a joke, and its meme-driven price antics aren't exactly a basis for enduring growth. If you're tired of losing money, it's probably a good idea to look for a few more serious investment options.

But that doesn't mean you'll need to dive into the realm of obscure stocks to find untouched new investments. In fact, the three companies I'll discuss today are in the top 50 of investing app Robinhood's most popular user holdings. More importantly, unlike Dogecoin, they're all great options for adding some long-term growth potential to your portfolio.

An person looks stressed sitting in the dark while looking at his computer screen.

Image source: Getty Images.

1. Johnson & Johnson

Johnson & Johnson (JNJ 1.08%) will never again grow as quickly as Dogecoin, but it won't collapse as suddenly, either. 

The healthcare giant didn't get to be one of the world's most valuable companies overnight or by the force of memes. Instead, it took decades building its current reputation for regularly growing its revenue, maintaining profitability, and delivering consistent returns to investors in the form of dividends and share buybacks. 

The key reason that Johnson & Johnson is better than Dogecoin is that the company actually makes things -- specifically, a plethora of consumer healthcare and pharmaceutical products that people need on a daily basis to survive. Though revenue from individual products such as Band-Aid bandages probably isn't huge in any given year, it adds up over the course of many products and several decades. And unlike Dogecoin, those cash flows aren't about to dry up overnight if people get bored of the Band-Aid brand; adhesive bandages will be needed either way.

The ongoing demand for Johnson & Johnson's goods supports the growth and safety of its dividend in the long term. For the past 58 years and counting, the business has raised its dividend payout like clockwork, making it a member of the elite squad of Dividend Kings that have demonstrated similarly enduring commitments. Right now, the stock's dividend yield is about 2.46%, which is higher than the S&P 500's average yield of 1.35%.

2. Moderna

Coronavirus vaccine maker Moderna (MRNA 1.59%) is another no-brainer Robinhood favorite to buy instead of Dogecoin. And unlike Johnson & Johnson, it's facing a handful of catalysts for growth in the near future, so it might even grow faster than Dogecoin does while still being at a lower risk of crashing. 

First, you may have heard that effective coronavirus vaccines are hot sellers. In the first quarter alone, Moderna made $1.7 billion from sales of its jab. Moving forward, the company is signing deals with countries including Taiwan, Japan, and Argentina to buy even more doses through 2022. That's sure to juice revenue growth even more, and the market is already reacting positively to the news. 

Second, Moderna is working on non-coronavirus projects, too. While its programs in the pipeline might take a few years to be commercialized (if they ever are), in the meantime they provide the company's investors with a road map to ensuring the revenue of tomorrow will be larger than the revenue of today. Of course, with Dogecoin, there's no way to even have a plan -- or any revenue. 

3. Catalyst Pharmaceuticals

As the riskiest stock that I'll discuss here, Catalyst Pharmaceuticals (CPRX 3.07%) is still far less of a gamble than Dogecoin. It's a small biotech company that's profitable, growing its revenue slowly, and battling against its shrinking earnings. 

Catalyst's one approved drug, for a rare autoimmune disease known as Lambert-Eaton myasthenic syndrome (LEMS), isn't exactly a cash cow. It made only $30.2 million in the first quarter, an increase of merely 3.7% year over year. That's hardly the kind of face-melting growth that Dogecoin investors are seeking. 

But there's more to the company than that one drug. Management plans to increase research and development (R&D) spending this year, and it's looking to acquire other promising small biotechs as well. That means things could turn around. There are people in the driver's seat working to use the company's assets to increase the future returns to shareholders. 

In other words: Catalyst's growth prospects and its financial performance are capable of changing. And when those things do change, the market's valuation of the stock will, too. With Dogecoin, there's no way to have any of the above.

Alex Carchidi owns shares of Catalyst Pharmaceuticals. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$178.00 (1.08%) $1.91
Catalyst Pharmaceuticals Stock Quote
Catalyst Pharmaceuticals
$16.77 (3.07%) $0.50
Moderna Stock Quote
$175.91 (1.59%) $2.76
Dogecoin Stock Quote
$0.11 (5.34%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.